Semin Neurol 2015; 35(06): 675-682
DOI: 10.1055/s-0035-1564684
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neuro-Oncologic Emergencies

Brian J. Scott
1   Department of Neurology, Lahey Hospital and Medical Center, Burlington, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
23 November 2015 (online)

Abstract

Cancer can have diverse and widespread effects on the nervous system. Knowledge of the most common characteristic mechanisms by which cancer impacts the nervous system enables prompt diagnosis and appropriate management. Here, a variety of neuro-oncologic emergencies are reviewed. Mass effect, status epilepticus, pituitary apoplexy, and metastatic epidural spinal cord compression are emergencies that arise from direct effects of central nervous system neoplasms. Limbic encephalitis may result in hospitalization and at times critical illness, and is usually caused by antibody-mediated reactions to neoplasms. Treatment-related neuro-oncologic emergencies from the effects of radiation and chemotherapy in severe cases may also result in medical emergencies.

 
  • References

  • 1 Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol 2007; 81 (1) 61-65
  • 2 Ostrom QT, Gittleman H, Liao P , et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 2014; 16 (Suppl. 04) iv1-iv63
  • 3 Howlader N, Noone AM, Krapcho M , et al. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2012/ . Accessed June 29, 2015
  • 4 Linn J, Brückmann H. Differential diagnosis of nontraumatic intracerebral hemorrhage. Klin Neuroradiol 2009; 19 (1) 45-61
  • 5 van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6 (5) 421-430
  • 6 Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004; 79 (12) 1489-1494
  • 7 Kong X, Guan J, Yang Y, Li Y, Ma W, Wang R. A meta-analysis: do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures?. Clin Neurol Neurosurg 2015; 134: 98-103
  • 8 Marcuse LV, Lancman G, Demopoulos A, Fields M. Nonconvulsive status epilepticus in patients with brain tumors. Seizure 2014; 23 (7) 542-547
  • 9 Betjemann JP, Nguyen I, Santos-Sanchez C, Douglas VC, Josephson SA. Diagnostic yield of electroencephalography in a general inpatient population. Mayo Clin Proc 2013; 88 (4) 326-331
  • 10 DeLorenzo RJ, Hauser WA, Towne AR , et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46 (4) 1029-1035
  • 11 Brophy GM, Bell R, Claassen J , et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (1) 3-23
  • 12 Cloughesy TF, Wen PY, Robins HI , et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006; 24 (22) 3651-3656
  • 13 Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2 (7) 404-409
  • 14 Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12 (2) 217-219
  • 15 Chang EF, Potts MB, Keles GE , et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008; 108 (2) 227-235
  • 16 Johnston PC, Hamrahian AH, Weil RJ, Kennedy L. Pituitary tumor apoplexy. J Clin Neurosci 2015; 22 (6) 939-944
  • 17 Rajasekaran S, Vanderpump M, Baldeweg S , et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) 2011; 74 (1) 9-20
  • 18 Bach F, Larsen BH, Rohde K , et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990; 107 (1–2) 37-43
  • 19 Savage P, Sharkey R, Kua T , et al. Malignant spinal cord compression: NICE guidance, improvements and challenges. QJM 2014; 107 (4) 277-282
  • 20 Barron KD, Hirano A, Araki S, Terry RD. Experiences with metastatic neoplasms involving the spinal cord. Neurology 1959; 9 (2) 91-106
  • 21 Thawait SK, Kim J, Klufas RA , et al. Comparison of four prediction models to discriminate benign from malignant vertebral compression fractures according to MRI feature analysis. AJR Am J Roentgenol 2013; 200 (3) 493-502
  • 22 Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ 1998; 317 (7150) 18-21
  • 23 Patchell RA, Tibbs PA, Regine WF , et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366 (9486) 643-648
  • 24 Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia 2009; 50 (Suppl. 12) 58-60
  • 25 Nassan G, Irani S, Bettcher B, Geschwind M, Gelfand J. Bradycardia leading to pacemaker placement: a characteristic prodromal syndrome of VGKCC/LGI1 antibody associated encephalitis. Neurol (Tokyo) 2014; 82 (10) (Suppl. 05) 195
  • 26 Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 2013; 14 (4) 528-538
  • 27 Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9 (5) 453-461
  • 28 Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006; 65 (2) 499-508
  • 29 Wen PY, Macdonald DR, Reardon DA , et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11) 1963-1972
  • 30 Levin VA, Bidaut L, Hou P , et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79 (5) 1487-1495
  • 31 Baehring JM, Fulbright RK. Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 2008; 79 (5) 535-539
  • 32 Carson KR, Newsome SD, Kim EJ , et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014; 120 (16) 2464-2471
  • 33 Mateen FJ, Muralidharan R, Carone M , et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70 (2) 305-322
  • 34 Roth C, Ferbert A. Posterior reversible encephalopathy syndrome: long-term follow-up. J Neurol Neurosurg Psychiatry 2010; 81 (7) 773-777
  • 35 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
  • 36 Dorth JA, Patel PR, Broadwater G, Brizel DM. Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy. Head Neck 2014; 36 (2) 215-219